AQST — Aquestive Therapeutics, Inc.

Summary of AQST (Aquestive Therapeutics, Inc.) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $13 million, up 10% from $11.9 million in Q4 2024, driven by increased manufacturer and supply revenue.
• Full Year 2025 Revenue: $44.5 million, down from $57.6 million in 2024, primarily due to a one-time recognition of deferred revenue in the prior year.
• Net Loss (Q4 2025): $31.9 million ($0.26 per share), compared to a loss of $17.1 million ($0.19 per share) in Q4 2024. The increase was attributed to higher legal and commercial expenses.
• Full Year 2025 Net Loss: $83.8 million ($0.78 per share), up from $44.1 million ($0.51 per share) in 2024.
• Cash Position: Ended 2025 with $121.2 million in cash, providing a runway for upcoming expenses related to ANNAFILM.

2. Strategic Updates and Business Highlights

• ANNAFILM Development: A clear path to resubmission of the NDA for ANNAFILM is established, with a Type A meeting with the FDA expected within 30 days. The company plans to file the resubmission by Q3 2026.
• Commercial Strategy: The sales force will increase by 50%, from 50 to 75 representatives, to enhance market penetration upon approval.
• Partnerships: RTW has extended its revenue-sharing agreement and committed an additional $5 million investment, indicating strong investor confidence.
• Market Opportunity: The overall allergy market is growing, with a significant portion of prescriptions still held by auto-injectors, indicating a strong demand for ANNAFILM as a potential oral alternative.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $46 million and $50 million, with a non-GAAP adjusted EBITDA loss projected between $30 million and $35 million.
• Cash Guidance for 2026: Anticipated to end the year with approximately $70 million, excluding additional proceeds from RTW or out-licensing transactions.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a significant increase in net losses due to rising legal and administrative expenses, which could raise concerns about financial sustainability.
• Regulatory Risks: The upcoming Type A meeting with the FDA carries inherent risks, and any delays or additional requirements could impact timelines.
• Market Competition: The competitive landscape remains challenging, particularly with aggressive DTC marketing from competitors, which could affect market share upon launch.

5. Notable Q&A Insights

• FDA Interaction: The company confirmed the Type A meeting with the FDA is scheduled soon, focusing on aligning on trial designs and requirements.
• Sales Strategy: The decision to increase the sales force is based on a strategic assessment of market needs and territory coverage to enhance efficiency.
• Clinical Development of AQST-108: While ANNAFILM is prioritized, the company is committed to progressing AQST-108, with potential for exploring multiple indications.
• Market Insights from Quad AI Conference: Feedback from allergists indicates strong interest and anticipation for ANNAFILM, reinforcing the product's potential in the market.

In summary, Aquestive Therapeutics is positioned for potential growth with ANNAFILM, despite facing challenges related to increased losses and regulatory hurdles. The company is optimistic about its strategic initiatives and market opportunities moving into 2026.